Treatment of chronic hepatitis C: impact of combination therapy.

被引:0
作者
Davis G.L. [1 ]
机构
[1] Section of Hepatology Diseases, University of Florida, Health Center, PO Box 100214, Gainesville, 32610-0214, FL
关键词
Interferon; Chronic Hepatitis; Sustained Virologic Response; Sustained Response; Sustained Viral Response;
D O I
10.1007/s11894-999-0080-9
中图分类号
学科分类号
摘要
Interferon as a single agent results in normalization of the serum alanine aminotransferase (ALT) levels, loss of detectable serum hepatitis C virus RNA, and histologic improvement in approximately 40% of patients. However, regardless of the duration of initial therapy, most patients relapse within the first few months after the drug is stopped, and only a small proportion have a sustained response. Ribavirin is a nucleoside analogue that is known to have in vitro activity against a number of both RNA and DNA viruses. As a single agent, oral ribavirin treatment transiently lowers serum ALT values into the normal range in about 40% of cases of chronic hepatitis C, but it does not affect the level of viremia. However, when given in combination with interferon for 6 to 12 months, ribavirin results in a sustained normalization of serum ALT levels and loss of detectable hepatitis C virus RNA in 30% to 40% of previously untreated patients. Retreatment of interferon relapsers with the combination of interferon and oral ribavirin for 6 months results in a sustained viral-negative response in about half of patients. Thus far, there is little evidence that combination therapy is effective in patients in whom ALT fails to normalize and who have lost hepatitis C virus RNA during a previous treatment course (nonresponders). Studies are ongoing in this group.
引用
收藏
页码:9 / 14
页数:5
相关论文
共 141 条
  • [1] Davis GL(1989)Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study N Engl J Med 321 1501-1506
  • [2] Balart LA(1995)Hepatic hepatitis C virus RNA as a predictor of long term response to interferona therapy Ann Intern Med 122 586-591
  • [3] Schiff ER(1995)A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis N Engl J Med 332 1457-1462
  • [4] Shindo M(1996)Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Hepatology 24 778-789
  • [5] Arai K(1997)Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 226-231
  • [6] Sokawa Y(1990)Molecular action of ribavirin Rev Infect Dis 12 1132-1146
  • [7] Okuna T(1998)Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response J Immunol 160 3487-3493
  • [8] Poynard T(1998)Alfa-interferon and ribavirin vs alfa-interferon alone as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled study Lancet 351 83-87
  • [9] Bedossa P(1997)Early changes in HCV RNA kinetics with interferon and ribavirin compared to interferon alone suggest an additive antiviral effect with ribavirin [abstract] Hepatology 26 367A-367A
  • [10] Chevallier M(1998)Daily high-dose interferon suppresses viremia in patients with chronic hepatitis C without a previous sustained response to standard treatment [abstract] Gastroenterology 114 A1248-A1248